Published in Pipeline

FDA clears IND for Oculis' privosegtor program expansion

This is editorially independent content
5 min read

The FDA has cleared an investigational new drug (IND) application for Oculis Holding AG to expand its privosegtor clinical program beyond optic neuritis (ON).

Its new indication target: acute multiple sclerosis (MS) relapses.

Let’s take a closer look at this candidate.

The highlights:

  • Privosegtor is a novel peptoid small molecule asset that acts as a serum-glucose corticoid kinase-2 (SGK-2) activator to penetrate the blood-brain and retinal barrier.
  • Its mechanism of action involves preserving the retina and improving visual function.

And in recent news: Oculis purchased the global development and commercial rights for privosegtor this past August.

And as for its clinical indications?

The most prominent indication we’ve reported on thus far is ON, for which phase 3 patient dosing has already kicked off and the FDA has granted two designations:

Check out more on this phase 3 Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research (PIONEER) program.

Talk clinical data thus far.

The phase 2 Acute OptiC NeUrITis of DemYelinating Origin (ACUITY; NCT04762017) trial evaluated ON patients—both with and without MS—treated with a daily dosing of privosegtor.

The findings: The study met its primary safety endpoint, with the asset demonstrating “promising neuroprotective” effects such as:

  • Improving visual function
  • Preserving retinal ganglion cell (RGC) layer integrity
  • Reducing blood levels of:
    • Neurofilament light chain (NfL), a biomarker of axonal injury
    • Glial fibrillary acidic protein (GFAP), a biomarker of astrocytic activation

Any findings yet from that phase 3 study?

Nope. PIONEER-1 (which mirrors the ACUITY trial in its design and participant criteria) is still undergoing patient dosing.

Considering it’s not expected to conclude until December 2027, we may be a few months out from seeing any topline data.

Alrighty, now let’s get to this latest update.

To set the stage: The FDA’s IND clearance comes after an early meeting with the agency’s neurology team, held before Oculis formally applied to start the trial.

Based on that meeting: The FDA confirmed Oculis can reuse safety and research data already submitted for privosegtor in its ophthalmic program.

So what’s the plan for this MS trial?

The FDA backed Oculis’s proposed plan for a clinical study evaluating patients diagnosed with MS who experience ON and other types of relapses (including ambulatory).

Some details:

  • Its primary endpoint will be targeted as early as 3 months.
  • The privosegtor dosage evaluated will be 3 mg/kg daily for 5 days.
    • To note: This matches the dosage administered in the PIONEER-1 and ACUITY studies (for ON).

And can you refresh me on the ON-MS connection?

ON is known as a common first sign of multiple sclerosis (MS), appearing as the first symptom in an estimated 15% to 20% of patients later diagnosed with MS.

Some supporting data behind this connection:

  • In the landmark Optic Neuritis Treatment Trial, ON patients had a 50% chance of developing MS within 15 years.
    • That risk was higher (72%) for those who had lesions on brain MRI at the start and 25% for those who had none.
  • The optic nerve is now formally part of how MS is diagnosed.

So this move from an ON to MS trial makes sense.

Indeed. Oculis even noted that, based on privosegtor’s positive ON phase 2 outcomes, “expanding into acute MS relapses is a natural evolution for the privosegtor program.”

And what’s the big-picture potential for privosegtor here?

It’s two part, with the asset tentatively poised to become the first neuropathic therapy for:

  • Actively preserving nerve integrity during acute MS relapses
  • Acute ON (AON) and non-arteritic anterior ischemic optic neuropathy (NAION)
    • Worth a reminder: The FDA recently mandated the addition of NAION to the warning label of all GLP-1RA drugs sold across the United States.

Lastly: Do we know when this MS-indicated trial will kick off?

No details as of yet. However, the company will host a research & development (R&D) day next month (Dec. 8) to share further updates on this indication—as well as its ongoing PIONEER program.

As always, stay tuned!